MedTrace Logo

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

NCT01151670 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-08-01

No results posted yet for this study

Summary

RATIONALE: Pioglitazone hydrochloride may be effective treatment for cognitive dysfunction caused by radiation therapy.

PURPOSE: This phase I trial is studying the side effects and best dose of pioglitazone hydrochloride in preventing radiation-induced cognitive dysfunction in treating patients with brain tumors.

Conditions

  • Brain Neoplasms, Malignant
  • Brain Neoplasms, Benign
  • Malignant Meningioma
  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma

Interventions

DRUG

pioglitazone

Pioglitazone 22.5 mg daily before, during and after radiation therapy.

DRUG

Pioglitazone

Pioglitazone 45 mg by mouth daily before, during and after radiation therapy

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Michael Chan · Wake Forest University Health Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-08-31
Completion
2014-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151670 on ClinicalTrials.gov